Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002435 · ClinicalTrials.gov registry record · Phase 2
A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients
A Phase 2 study of HIV Infections, sponsored by Pharmacia.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Study locations
NCT00002435 is a Phase 2 study of HIV Infections that has completed, run by Pharmacia. The trial reports 10 study locations across 6 states.
The verdict
NCT00002435, a Phase 2 study of HIV Infections, has completed, sponsored by Pharmacia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10
- Study locations
Study Summary
To investigate the safety of thymic humoral factor (THF gamma 2), its effect on HIV load based on at least a 75 percent decrease in HIV quantitative PCR RNA copies/ml, and its persistence when administered in combination with an antiretroviral nucleoside derivative (zidovudine; AZT). To assess the effects of THF gamma 2 on T-cells, quality of life, and progression of disease.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG Thymic Humoral Factor
Study Locations (10)
California
- UCI - Irvine
- Southwest Community Based AIDS Treatment Group - COMBAT - Los Angeles
- San Francisco Veterans Administration Med Ctr - San Francisco
- Gottlieb Med Group - Sherman Oaks
Florida
- Mem Hosp Hollywood - Hollywood
- Goodgame Med Group - Maitland
New York
- Chelsea Village Med Ctr - New York
Oregon
- Portland Veterans Adm Med Ctr / Rsch & Education Grp - Portland
South Carolina
- Dr Alfred F Burnside Jr - Columbia
Virginia
- Infectious Disease Physicians Inc - Annandale
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002435
The ClinicalTrials.gov registry entry for NCT00002435 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pharmacia, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Zidovudine is the first listed.
NCT00002435 reports 10 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00002435 about?
NCT00002435 is a clinical study titled "A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients". To investigate the safety of thymic humoral factor (THF gamma 2), its effect on HIV load based on at least a 75 percent decrease in HIV quantitative PCR RNA copies/ml, and its persistence when administered in combination with an antiretroviral nucleoside derivative (zidovudine; AZT). To assess the e...
What is the current status of trial NCT00002435?
This trial is currently completed. It is a Phase 2 study.
What conditions does trial NCT00002435 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002435?
The interventions under investigation include: Zidovudine (DRUG), Thymic Humoral Factor (DRUG).
Who is sponsoring clinical trial NCT00002435?
This trial is sponsored by Pharmacia, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002435 being conducted?
This trial has 10 study locations across California, Florida, New York, Oregon, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.